Literature DB >> 21538024

The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival.

Anna G Antonacopoulou1, Konstantina Floratou, Vasiliki Bravou, Anastasia Kottorou, Fotinos-Ioannis Dimitrakopoulos, Stella Marousi, Michalis Stavropoulos, Angelos K Koutras, Chrisoula D Scopa, Haralabos P Kalofonos.   

Abstract

BACKGROUND: Survivin is involved in the regulation of cell division and survival, two key processes in cancer. The majority of studies on survivin in colorectal cancer (CRC) have focused on protein expression and less is known about the expression of survivin splicing variants or survivin gene polymorphisms in CRC. In the present study, the mRNA levels of the five known isoforms of survivin as well as survivin protein were assessed in matched normal and neoplastic colorectal tissue. Moreover, the 9386 C/T and -31 G/C polymorphisms were investigated.
METHODS: Quantitative RT-PCR was used to assess mRNA levels in fresh/frozen tissue samples. Protein levels were immunohistochemically evaluated on formalin-fixed paraffin-embedded tissue sections. Individuals were genotyped using real time PCR.
RESULTS: Expression of all 5 survivin splice variants as well as survivin protein was elevated in colorectal carcinomas compared to normal tissue. Specific splice variant expression differentially correlated with clinicopathological parameters. Furthermore, both snps correlated with splice variant levels or their ratios in colorectal carcinomas while the -31 G/C snp may be related to CRC development and improved overall survival.
CONCLUSION: Our results support a role of survivin in colorectal carcinogenesis while the -31 G/C snp may constitute a marker of survival.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21538024     DOI: 10.1007/s13402-011-0038-4

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  38 in total

Review 1.  Survivin study: an update of "what is the next wave"?

Authors:  Fengzhi Li; Xiang Ling
Journal:  J Cell Physiol       Date:  2006-09       Impact factor: 6.384

Review 2.  Survivin study: what is the next wave?

Authors:  Fengzhi Li
Journal:  J Cell Physiol       Date:  2003-10       Impact factor: 6.384

3.  Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?

Authors:  Paul N Span; Vivianne C G Tjan-Heijnen; Joop J T M Heuvel; Jacques B de Kok; John A Foekens; Fred C G J Sweep
Journal:  Clin Chem       Date:  2006-07-27       Impact factor: 8.327

4.  Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation.

Authors:  Rajesh Kannangai; Jianzhou Wang; Qiong Z Liu; Fikret Sahin; Michael Torbenson
Journal:  Int J Gastrointest Cancer       Date:  2005

5.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties.

Authors:  C Mahotka; M Wenzel; E Springer; H E Gabbert; C D Gerharz
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

6.  Distinct expression of Survivin splice variants in breast carcinomas.

Authors:  Frédérique Vegran; Romain Boidot; Claire Oudin; Jean-Marc Riedinger; Sarab Lizard-Nacol
Journal:  Int J Oncol       Date:  2005-10       Impact factor: 5.650

7.  Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas.

Authors:  Keiji Suga; Tetsuhisa Yamamoto; Yoshitaka Yamada; Shin-Ichi Miyatake; Toshimasa Nakagawa; Nobuhiko Tanigawa
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

8.  Nuclear translocation of survivin in hepatocellular carcinoma: a key to cancer cell growth?

Authors:  Woo Sung Moon; Andrzej S Tarnawski
Journal:  Hum Pathol       Date:  2003-11       Impact factor: 3.466

9.  POLR2F, ATP6V0A1 and PRNP expression in colorectal cancer: new molecules with prognostic significance?

Authors:  Anna G Antonacopoulou; Petros D Grivas; Lambros Skarlas; Melpomeni Kalofonos; Chrisoula D Scopa; Haralabos P Kalofonos
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

10.  Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy.

Authors:  Silke Lassmann; Laura Tang; Marinela Capanu; Thomas Brabletz; Anja Schöpflin; Axel Zur Hausen; Mithat Gonen; Nancy Kemeny; Jinru Shia; David Klimstra; Martin Werner
Journal:  Gastroenterology       Date:  2007-09-05       Impact factor: 22.682

View more
  14 in total

1.  Technical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.

Authors:  Shenli Zhang; Iain B Tan; Nur S Sapari; Heike I Grabsch; Alicia Okines; Elizabeth C Smyth; Toru Aoyama; Lindsay C Hewitt; Imran Inam; Dan Bottomley; Matthew Nankivell; Sally P Stenning; David Cunningham; Andrew Wotherspoon; Akira Tsuburaya; Takaki Yoshikawa; Richie Soong; Patrick Tan
Journal:  J Mol Diagn       Date:  2015-03-04       Impact factor: 5.568

Review 2.  Survivin at a glance.

Authors:  Sally P Wheatley; Dario C Altieri
Journal:  J Cell Sci       Date:  2019-04-04       Impact factor: 5.285

3.  Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population.

Authors:  Xia-Bin Li; Shi-Ning Li; Zhi-Hui Yang; Ling Cao; Fang-Lei Duan; Xing-Wang Sun
Journal:  DNA Cell Biol       Date:  2013-04-12       Impact factor: 3.311

4.  Survivin -31 G/C polymorphism might contribute to colorectal cancer (CRC) risk: a meta-analysis.

Authors:  Linhua Yao; Yi Hu; Zhongmin Deng; Jingjing Li
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 5.  Clinico-pathologic relevance of Survivin splice variant expression in cancer.

Authors:  Rosalia de Necochea-Campion; Chien-Shing Chen; Saied Mirshahidi; Frank D Howard; Nathan R Wall
Journal:  Cancer Lett       Date:  2013-06-18       Impact factor: 8.679

Review 6.  Association between survivin -31G>C polymorphism and cancer risk: meta-analysis of 29 studies.

Authors:  Qin Qin; Chi Zhang; Hongcheng Zhu; Xi Yang; Liping Xu; Jia Liu; Jing Lu; Liangliang Zhan; Hongyan Cheng; Xinchen Sun
Journal:  J Cancer Res Clin Oncol       Date:  2014-02       Impact factor: 4.553

7.  Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: an updated meta-analysis of 26 studies.

Authors:  Lei Xu; Xin Zhou; Lin Xu; Rong Yin
Journal:  Tumour Biol       Date:  2013-10-05

Review 8.  Survivin: A molecular biomarker in cancer.

Authors:  Praveen Kumar Jaiswal; Apul Goel; R D Mittal
Journal:  Indian J Med Res       Date:  2015-04       Impact factor: 2.375

9.  Association of survivin polymorphisms with tumor susceptibility: a meta-analysis.

Authors:  Ying Zhu; Yongguo Li; Shisheng Zhu; Renkuan Tang; Yunzhi Liu; Jianbo Li
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

10.  Analysis of the functional repertoire of a mutant form of survivin, K129E, which has been linked to lung cancer.

Authors:  Aysha M Aljaberi; Jamie Rm Webster; Sally P Wheatley
Journal:  Cancer Cell Int       Date:  2014-08-19       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.